Encoded Therapeutics will further develop its lead precision gene therapy platform for Dravet syndrome and other severe genetic…
Articles by Patricia Inácio, PhD
Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational…
Epygenix Therapeutics has submitted an investigational new drug application (IND) to the U.S. Food and Drug…
Zogenix‘s investigational therapy Fintepla (ZX008) to treat epileptic seizures associated with Dravet syndrome will be marketed…
Epidiolex (cannabidiol) oral solution is now available in the United States as a treatment for seizures in patients age 2…
Treatment with stiripentol reduces seizures and can resolve epileptic episodes, retrospective analysis of a small study in Turkish Dravet syndrome…
Fenfluramine, originally developed as an appetite suppressant, shows potential as an anti-epileptic therapy to reduce the seizure rate in…
The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment…
Supernus Pharmaceuticals now holds the worldwide rights — except in certain markets in Asia — to develop the…
The U.S. Food and Drug Administration (FDA) has approved Biocodex’s Diacomit (stiripentol) as an add-on therapy for seizures associated…